Chimpanzee Adenovirus Vector Ebola Vaccine
Julie E Ledgerwood, Adam D DeZure, Daphne A Stanley, Emily E Coates, Laura Novik, Mary E Enama, Nina M Berkowitz, Zonghui Hu, Gyan Joshi, Aurélie Ploquin, Sandra Sitar, Ingelise J Gordon, Sarah A Plummer, LaSonji A Holman, Cynthia S Hendel, Galina Yamshchikov, Francois Roman, Alfredo Nicosia, Stefano Colloca, Riccardo Cortese, Robert T Bailer, Richard M Schwartz, Mario Roederer, John R Mascola, Richard A Koup, Nancy J Sullivan, Barney S Graham, VRC 207 Study Team, Pamela Costner, Floreliz Mendoza, Jamie Saunders, Kathy Zephir, Brenda Larkin, William Whalen, Olga Vasilenko, Iris Pittman, Carmencita Artis, Brandon Wilson, Emily Coates, Christine Nguyen, Pernell Williams, John Gilly, Florence Kaltovich, Michelle Conan-Cibotti, Gretchen Schieber, Judy Stein, Judith Starling, Hope Decederfelt, Phyllis Renehan, Sarah Romano, Julie E Ledgerwood, Adam D DeZure, Daphne A Stanley, Emily E Coates, Laura Novik, Mary E Enama, Nina M Berkowitz, Zonghui Hu, Gyan Joshi, Aurélie Ploquin, Sandra Sitar, Ingelise J Gordon, Sarah A Plummer, LaSonji A Holman, Cynthia S Hendel, Galina Yamshchikov, Francois Roman, Alfredo Nicosia, Stefano Colloca, Riccardo Cortese, Robert T Bailer, Richard M Schwartz, Mario Roederer, John R Mascola, Richard A Koup, Nancy J Sullivan, Barney S Graham, VRC 207 Study Team, Pamela Costner, Floreliz Mendoza, Jamie Saunders, Kathy Zephir, Brenda Larkin, William Whalen, Olga Vasilenko, Iris Pittman, Carmencita Artis, Brandon Wilson, Emily Coates, Christine Nguyen, Pernell Williams, John Gilly, Florence Kaltovich, Michelle Conan-Cibotti, Gretchen Schieber, Judy Stein, Judith Starling, Hope Decederfelt, Phyllis Renehan, Sarah Romano
Abstract
Background: The unprecedented 2014 epidemic of Ebola virus disease (EVD) prompted an international response to accelerate the availability of a preventive vaccine. A replication-defective recombinant chimpanzee adenovirus type 3-vectored ebolavirus vaccine (cAd3-EBO), encoding the glycoprotein from Zaire and Sudan species, that offers protection in the nonhuman primate model, was rapidly advanced into phase 1 clinical evaluation.
Methods: We conducted a phase 1, dose-escalation, open-label trial of cAd3-EBO. Twenty healthy adults, in sequentially enrolled groups of 10 each, received vaccination intramuscularly in doses of 2×1010 particle units or 2×1011 particle units. Primary and secondary end points related to safety and immunogenicity were assessed throughout the first 8 weeks after vaccination; in addition, longer-term vaccine durability was assessed at 48 weeks after vaccination.
Results: In this small study, no safety concerns were identified; however, transient fever developed within 1 day after vaccination in two participants who had received the 2×1011 particle-unit dose. Glycoprotein-specific antibodies were induced in all 20 participants; the titers were of greater magnitude in the group that received the 2×1011 particle-unit dose than in the group that received the 2×1010 particle-unit dose (geometric mean titer against the Zaire antigen at week 4, 2037 vs. 331; P=0.001). Glycoprotein-specific T-cell responses were more frequent among those who received the 2×1011 particle-unit dose than among those who received the 2×1010 particle-unit dose, with a CD4 response in 10 of 10 participants versus 3 of 10 participants (P=0.004) and a CD8 response in 7 of 10 participants versus 2 of 10 participants (P=0.07) at week 4. Assessment of the durability of the antibody response showed that titers remained high at week 48, with the highest titers in those who received the 2×1011 particle-unit dose.
Conclusions: Reactogenicity and immune responses to cAd3-EBO vaccine were dose-dependent. At the 2×1011 particle-unit dose, glycoprotein Zaire-specific antibody responses were in the range reported to be associated with vaccine-induced protective immunity in challenge studies involving nonhuman primates, and responses were sustained to week 48. Phase 2 studies and efficacy trials assessing cAd3-EBO are in progress. (Funded by the Intramural Research Program of the National Institutes of Health; VRC 207 ClinicalTrials.gov number, NCT02231866 .).
Source: PubMed